Albinterferon Alfa-2B

Summary

Albinterferon alfa-2b (trade name Joulferon) is a long-acting fusion protein combining human serum albumin with interferon alfa-2b, developed by Human Genome Sciences and Novartis for the treatment of chronic hepatitis C. Despite completing Phase III clinical trials showing non-inferiority to peginterferon alfa-2a, the drug was withdrawn from development in 2010 due to pulmonary adverse events and strategic business decisions.

Mechanism of Action

Albinterferon alfa-2b is a genetic fusion of human serum albumin with interferon alfa-2b. It activates the JAK-STAT signaling pathway (JAK1 and TYK2) upon binding to the type I interferon receptor (IFNAR1/IFNAR2), inducing antiviral, antiproliferative, and immunomodulatory effects. Fusion with albumin extends the half-life significantly, allowing less frequent dosing.

Routes of Administration

Goals & Uses

• Reduced dosing frequency vs. standard interferonPharmacokinetic AdvantageModerate
• Chronic Hepatitis C treatment (genotype 1)Antiviral / HepatologyModerate
• Chronic Hepatitis C treatment (genotypes 2/3)Antiviral / HepatologyModerate

Contraindications

• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Autoimmune hepatitisHepatic / AutoimmuneHigh
• Decompensated liver disease / Child-Pugh B or C cirrhosisHepaticHigh
• Severe psychiatric disorders (e.g., suicidal ideation)PsychiatricHigh
• Hypersensitivity to interferon alfa or albuminImmunologic / AllergicHigh

Adverse Effects

• Hematologic toxicity (neutropenia, thrombocytopenia, anemia)HematologicCommon
• Injection site reactionsLocalCommon
• Thyroid dysfunction (hypothyroidism or hyperthyroidism)EndocrineUncommon
• Flu-like symptoms (fever, chills, myalgia, fatigue)Systemic / ConstitutionalCommon
• Pulmonary adverse events (cough, dyspnea, interstitial pneumonitis)RespiratoryUncommon
• Neuropsychiatric effects (depression, irritability, insomnia)Psychiatric / NeurologicalCommon

Drug Interactions

• Theophylline / MethylxanthinesModerate
• RibavirinModerate
• ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
• Nucleoside analogues (e.g., zidovudine, didanosine)Moderate

Population Constraints

• Pediatric patientsAgeRelative
• Patients with pre-existing pulmonary diseaseRespiratoryRelative
• Elderly patients (>65 years)AgeRelative
• Patients with pre-existing psychiatric conditionsPsychiatricRelative
• Renal impairment (severe)RenalRelative

Regulatory Status

• European UnionUnapprovedEMA marketing authorization application withdrawn; never received approval in the EU.
• United StatesUnapprovedDevelopment and regulatory submissions withdrawn in 2010 before FDA approval; never approved.
• United KingdomUnapprovedNever approved in the UK; development discontinued globally prior to any regulatory approval.

Development was halted in 2010 following safety concerns, particularly pulmonary adverse events (cough, dyspnea) observed in Phase III trials. Regulatory submissions were withdrawn before approval in any jurisdiction. Never received marketing authorization from FDA, EMA, or other major regulatory bodies.

Evidence & Sources

No sources recorded yet.